miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosis

Loffreda, Alessia; Nizzardo, Monica; Arosio, Alessandro; Ruepp, Marc-David; Calogero, Raffaele A.; Volinia, Stefano; Galasso, Marco; Bendotti, Caterina; Ferrarese, Carlo; Lunetta, Christian; Rizzuti, Mafalda; Ronchi, Antonella; Mühlemann, Oliver; Tremolizzo, Lucio; Corti, Stefania; Barabino, Silvia M.L. (2020). miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosis. Progress in neurobiology, 190, p. 101803. Elsevier 10.1016/j.pneurobio.2020.101803

[img] Text
Loffreda et al., 2020_pre-proof.pdf - Accepted Version
Restricted to registered users only until 25 October 2021.
Available under License Publisher holds Copyright.

Download (942kB) | Request a copy
[img] Text
1-s2.0-S0301008220300587-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Amyotrophic lateral sclerosis (ALS) is a relentless and fatal neurological disease characterized by the selective degeneration of motor neurons. No effective therapy is available for this disease. Several lines of evidence indicate that alteration of RNA metabolism, including microRNA (miRNA) processing, is a relevant pathogenetic factor and a possible therapeutic target for ALS. Here, we showed that the abundance of components in the miRNA processing machinery is altered in a SOD1-linked cellular model, suggesting consequent dysregulation of miRNA biogenesis. Indeed, high-throughput sequencing of the small RNA fraction showed that among the altered miRNAs, miR-129-5p was increased in different models of SOD1-linked ALS and in peripheral blood cells of sporadic ALS patients. We demonstrated that miR-129-5p upregulation causes the downregulation of one of its targets: the RNA-binding protein ELAVL4/HuD. ELAVL4/HuD is predominantly expressed in neurons, where it controls several key neuronal mRNAs. Overexpression of pre-miR-129-1 inhibited neurite outgrowth and differentiation via HuD silencing in vitro, while its inhibition with an antagomir rescued the phenotype. Remarkably, we showed that administration of an antisense oligonucleotide (ASO) inhibitor of miR-129-5p to an ALS animal model, SOD1 (G93A) mice, result in a significant increase in survival and improved the neuromuscular phenotype in treated mice. These results identify miR-129-5p as a therapeutic target that is amenable to ASO modulation for the treatment of ALS patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

08 Faculty of Science > Departement of Chemistry and Biochemistry

UniBE Contributor:

Ruepp, Marc-David and Mühlemann, Oliver

Subjects:

500 Science > 570 Life sciences; biology
500 Science > 540 Chemistry

ISSN:

1873-5118

Publisher:

Elsevier

Language:

English

Submitter:

Christina Schüpbach

Date Deposited:

12 May 2020 16:01

Last Modified:

07 Jun 2020 02:52

Publisher DOI:

10.1016/j.pneurobio.2020.101803

BORIS DOI:

10.7892/boris.143763

URI:

https://boris.unibe.ch/id/eprint/143763

Actions (login required)

Edit item Edit item
Provide Feedback